PL2846836T3 - Sposób leczenia amd u pacjentów opornych na terapię anty- vegf - Google Patents

Sposób leczenia amd u pacjentów opornych na terapię anty- vegf

Info

Publication number
PL2846836T3
PL2846836T3 PL13723356T PL13723356T PL2846836T3 PL 2846836 T3 PL2846836 T3 PL 2846836T3 PL 13723356 T PL13723356 T PL 13723356T PL 13723356 T PL13723356 T PL 13723356T PL 2846836 T3 PL2846836 T3 PL 2846836T3
Authority
PL
Poland
Prior art keywords
vegf therapy
patients refractory
treating amd
amd
treating
Prior art date
Application number
PL13723356T
Other languages
English (en)
Inventor
Thomas C. Hohman
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of PL2846836T3 publication Critical patent/PL2846836T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL13723356T 2012-05-07 2013-05-06 Sposób leczenia amd u pacjentów opornych na terapię anty- vegf PL2846836T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261643878P 2012-05-07 2012-05-07
US201261728017P 2012-11-19 2012-11-19
US201261731238P 2012-11-29 2012-11-29
EP13723356.5A EP2846836B1 (en) 2012-05-07 2013-05-06 Method of treating amd in patients refractory to anti-vegf therapy
PCT/US2013/039619 WO2013169614A1 (en) 2012-05-07 2013-05-06 Method of treating amd in patients refractory to anti-vegf therapy

Publications (1)

Publication Number Publication Date
PL2846836T3 true PL2846836T3 (pl) 2020-01-31

Family

ID=48446670

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13723356T PL2846836T3 (pl) 2012-05-07 2013-05-06 Sposób leczenia amd u pacjentów opornych na terapię anty- vegf

Country Status (10)

Country Link
US (3) US10568934B2 (pl)
EP (2) EP3646880A1 (pl)
AR (1) AR090972A1 (pl)
DK (1) DK2846836T3 (pl)
ES (1) ES2753135T3 (pl)
HU (1) HUE046134T2 (pl)
PL (1) PL2846836T3 (pl)
PT (1) PT2846836T (pl)
TW (1) TW201350128A (pl)
WO (1) WO2013169614A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3252079B8 (en) 2006-04-07 2020-09-09 Aerpio Therapeutics LLC Antibodies that bind human protein tyrosine phosphatase beta (hptp-beta) and uses thereof
CN104039351A (zh) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 用于治疗血管渗漏综合征和癌症的方法
WO2013169614A1 (en) * 2012-05-07 2013-11-14 Allergan, Inc. Method of treating amd in patients refractory to anti-vegf therapy
SMT202000088T1 (it) * 2013-02-18 2020-03-13 Vegenics Pty Ltd Molecole leganti ligandi e relativi usi
EP3628324A1 (en) * 2013-11-05 2020-04-01 Allergan, Inc. Method of treating conditions of the eye with an anti-vegf darpin
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
RU2712623C2 (ru) 2015-03-31 2020-01-30 Илдонг Фарм. Ко., Лтд. Фармацевтическая композиция для предотвращения и лечения заболеваний глаз, содержащая в качестве активного ингредиента белок слияния, в котором слиты проникающий в ткань пептид и препарат против фактора роста эндотелия сосудов
BR112018013407A2 (en) 2015-12-30 2018-12-18 Kodiak Sciences Inc. antibodies and conjugates thereof
HUE051953T2 (hu) * 2016-06-16 2021-04-28 Adverum Biotechnologies Inc Idõskori makula degeneráció kezelése AAV2 variáns és aflibercept alkalmazásával
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
US11519020B2 (en) * 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN120058958A (zh) 2018-09-24 2025-05-30 视点制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
KR20250051157A (ko) 2019-06-05 2025-04-16 리제너론 파아마슈티컬스, 인크. 정밀 투여량 전달을 위한 디바이스 및 방법
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69535829D1 (de) 1994-08-20 2008-10-16 Gendaq Ltd Verbesserung in bezug auf bindungsproteine bei der erkennung von dna
US5932440A (en) 1996-08-16 1999-08-03 Life Technologies, Inc. Mammalian ribonuclease inhibitors and use thereof
US5827692A (en) 1997-04-24 1998-10-27 Heska Corporation Dirofilaria and Brugia ankyrin proteins, nucleic acid molecules, and uses thereof
EP1009422A4 (en) 1997-07-18 2003-03-19 Univ Yale STRUCTURE OF THE ANKYRINE BONDING POINT OF AN ALPHA-NA, K-ATPASE
DK1137941T4 (da) 1998-12-10 2014-01-06 Brystol Myers Squibb Company Protein-scaffolds til antistof-mimetika og andre bindingsproteiner
RS50073B (sr) 1999-06-08 2009-01-22 Regeneron Pharmaceuticals I.N.C., Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama
US20020042094A1 (en) 1999-12-15 2002-04-11 Venezia Domenick R. RING finger protein zapop2
WO2001061005A2 (en) 2000-02-17 2001-08-23 Millennium Pharmaceuticals, Inc. Molecules of the pyrin domain protein family and uses thereof
US20020035739A1 (en) 2000-05-05 2002-03-21 Michael Lassner Evolution of plant disease response plant pathways to enable the development of based biological sensors and to develop novel disease resistance strategies
US6750057B2 (en) 2000-06-29 2004-06-15 University Of Florida Ubiquitin ligase
CA2421447C (en) 2000-09-08 2012-05-08 Universitat Zurich Collections of repeat proteins comprising repeat modules
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
JP5006651B2 (ja) 2003-12-05 2012-08-22 ブリストル−マイヤーズ スクウィブ カンパニー ２型血管内皮増殖因子受容体の阻害剤
US20060121045A1 (en) 2004-11-08 2006-06-08 Brent Iverson Antibody fragments for protection from pathogen infection and methods of use thereof
EP2863222A1 (en) 2006-03-06 2015-04-22 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
EP2121743B1 (en) 2006-11-22 2015-06-03 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
ATE516814T1 (de) 2007-02-02 2011-08-15 Bristol Myers Squibb Co 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
HRP20110368T1 (hr) 2007-06-21 2011-06-30 Technische Universitt Mnchen Biološki aktivni proteini s povećanom stabilnošću in vivo i/ili in vitro
EP2263088A2 (en) 2008-03-19 2010-12-22 Institut Pasteur Reagentless fluorescent biosensors comprising a designed ankyrin repeat protein module, rational design methods to create reagentless fluorescent biosensors and methods of their use
EP2358746B1 (en) 2008-11-03 2020-09-16 Molecular Partners AG Binding proteins inhibiting the vegf-a receptor interaction
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
EP2643349B1 (en) 2010-11-26 2019-09-04 Molecular Partners AG Designed repeat proteins binding to serum albumin
WO2013169614A1 (en) 2012-05-07 2013-11-14 Allergan, Inc. Method of treating amd in patients refractory to anti-vegf therapy
WO2014001442A1 (en) 2012-06-28 2014-01-03 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
EP3628324A1 (en) 2013-11-05 2020-04-01 Allergan, Inc. Method of treating conditions of the eye with an anti-vegf darpin

Also Published As

Publication number Publication date
EP2846836B1 (en) 2019-08-14
EP2846836A1 (en) 2015-03-18
EP3646880A1 (en) 2020-05-06
US20220096596A1 (en) 2022-03-31
WO2013169614A1 (en) 2013-11-14
PT2846836T (pt) 2019-10-29
HUE046134T2 (hu) 2020-02-28
US20200405808A1 (en) 2020-12-31
US10568934B2 (en) 2020-02-25
AR090972A1 (es) 2014-12-17
ES2753135T3 (es) 2020-04-07
DK2846836T3 (da) 2019-11-11
US20130296238A1 (en) 2013-11-07
TW201350128A (zh) 2013-12-16

Similar Documents

Publication Publication Date Title
HUE046134T2 (hu) Eljárás AMD kezelésére az anti-VEGF terápiára nem reagáló betegekben
LT2766014T (lt) Pediatrinių pacientų gydymo būdai, naudojant deksmedetomidiną
ZA201503332B (en) Water treatment composition and method of using same
IL237528A0 (en) Methods for preventing and treating preeclampsia
ZA201502230B (en) Methods and compositions for treatment and control of plant disease
GB201110095D0 (en) Method of treatment
EP2773754A4 (en) Methods of Treatment
IL237138A0 (en) Methods of administration of pirfenidone therapy
PT2827863T (pt) Composição líquida para utilização num método de tratamen-to de condições responsivas a bendamustina em pacientes que requerem volumes reduzidos para administração
IL230433A0 (en) Pain management methods
IL234606A0 (en) Innovative methods and compounds for the treatment of diseases
EP2894983A4 (en) METHOD FOR THE ADMINISTRATION OF RIFAXIMINE FOR WEIGHT REDUCTION AND TREATMENT OF GRAVITY
IL239273A0 (en) A method of treating diseases
SG11201504779YA (en) Methods and compositions relating to treatment of cancer
GB201120718D0 (en) Apparatus and method for treatment of patients
GB2520636B (en) Heat treatment for removal of bauschinger effect or to accelerate cement curing
EP2911662A4 (en) METHOD OF TREATING A DISEASE
PL2938755T3 (pl) Sposób powierzchniowej obróbki stali nierdzewnej
EP2791324A4 (en) PROCESSING METHOD
GB201221032D0 (en) Method of treatment
GB201207894D0 (en) Method of treatment
IL232661A0 (en) A method of treating pain by administering a bone growth factor
ZA201501068B (en) Methods for prevention and treatment of preeclampsia
GB201221118D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment